Page 178 - 2021_10-Haematologica-web

K.L. Yong et al.
review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica. 2018;103(9):1422-1432.
8. Besse A, Besse L, Kraus M, et al. Proteasome inhibition in multiple myeloma: head-to- head comparison of currently available pro- teasome inhibitors. Cell Chem Biol. 2019;26(3):340-351.
9. Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or borte- zomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, ran- domised, phase 3 trial. Lancet Oncol. 2017;18(10):1327-1337.
10.Facon T, Lee JH, Moreau P, et al. Randomized phase 3 study of carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible, NDMM patients. Blood. 2019;133(18):1953-1963
11.Kumar SK, Jacobus SJ, Cohen AD, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21(10):1317-1330
12. Bringhen S, Petruccim MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dex- amethasone in patients with newly diag- nosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124(1):63-69.
13. Bringhen S, D’Agostino M, De Paoli L, et al. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. Leukemia. 2018;32(4):979-985.
14.Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dex-
amethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009;23(7): 1337-1341.
15. Brown S, Hinsley S, Ballesteros M, et al. The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dex- amethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refracto- ry multiple myeloma. BMC Hematol. 2016;16:14.
16. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uni- form reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18): 4691-4695.
17. Rawstron AC, Chile JA, de Tute RM, et al. Minimal residual disease assessed by multi- parameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31(20):2540-2547.
18. de Tute RM, Rawstron AC, Cairns DA, et al. Impact of minimal residual disease in trans- plant ineligible myeloma patients: results from the UK NCRI Myeloma XI Trial. Blood. 2016;128(22):245.
19. Shah V, SherbournenAL, Walker BA, et al. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia. 2018;32(1):102-110.
20.Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a compet- ing risk. J Am Stat Ass. 2012:496-509.
21. Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probabili- ty of censoring weighted (IPCW) log-rank
tests. Biometrics. 2000;56(3):779-788.
22. Moreau P, Dimopoulos MA, Yong K, et al. Isatuximab plus carfilzomib/dexametha- sone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA phase III study design.
Future Oncol. 2020;16(2):4347-4358.
23. Moreau P, Stewart KA, Dimopoulos M, et al. Once-weekly (70 mg/m(2) ) vs twice-week- ly (56 mg/m(2) ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPI- ON-1 trials. Cancer Med. 2020;9(9):2989-
2996.
24. Moreau P, Mateos MV, Berenson JR, et al.
Once weekly versus twice weekly carfil- zomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19(7):953- 964.
25. Mina R, Bonello F, Petrucci MT, et al. Carfilzomib, cyclophosphamide and dex- amethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies. Haematologica. 2021;106(4):1079-1085.
26. Gregersen H, Peceliunas V, Remes K, et al. A randomized phase 2 trial comparing carfil- zomib-dexamethasone vs observation as maintenance after induction with carfil- zomib-cyclophosphamide-dexamethasone in salvage ASCT in multiple myeloma: a trial by the Nordic Myeloma Study Group. Blood. 2019;134(Suppl_1):601.
27. Bringhen S, Mina R, Petrucci MT, et al. Once-weekly versus twice-weekly carfil- zomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase 1/2 studies. Haematologica. 2019;104 (8):1640-1647.
2706
haematologica | 2021; 106(10)